[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2003231647A - Oral liquid composition - Google Patents

Oral liquid composition

Info

Publication number
JP2003231647A
JP2003231647A JP2002027757A JP2002027757A JP2003231647A JP 2003231647 A JP2003231647 A JP 2003231647A JP 2002027757 A JP2002027757 A JP 2002027757A JP 2002027757 A JP2002027757 A JP 2002027757A JP 2003231647 A JP2003231647 A JP 2003231647A
Authority
JP
Japan
Prior art keywords
liquid composition
oral liquid
fruit
taste
stevia extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002027757A
Other languages
Japanese (ja)
Other versions
JP4190769B2 (en
Inventor
Tatsuhiko Tsutsumi
龍彦 堤
Yoichiro Uchiumi
洋一郎 内海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruzen Pharmaceutical Co Ltd
Original Assignee
Maruzen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruzen Pharmaceutical Co Ltd filed Critical Maruzen Pharmaceutical Co Ltd
Priority to JP2002027757A priority Critical patent/JP4190769B2/en
Publication of JP2003231647A publication Critical patent/JP2003231647A/en
Application granted granted Critical
Publication of JP4190769B2 publication Critical patent/JP4190769B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To obtain an oral liquid composition that can be deliciously taken, even after active ingredients of medicines and foods having unpleasant tastes, e.g. bitterness and peculiarly unpleasant smells are continuously ingested or can be smoothly ingested even by children without vomiting because of strange tastes and unbearable smells. <P>SOLUTION: The oral liquid composition comprises (a) the active ingredients of medicines and foods having unpleasant tastes and smalls, (b) fruit perfumes and (c) a sweetener in combination of potassium acesulfam and a stevia extract at a mass ratio of the acesulfam/the stevia extruct of 10/(1-4). <P>COPYRIGHT: (C)2003,JPO

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、内服液組成物に関
し、更に詳述すると、配合される医薬食品有効成分の有
する苦味、渋味、エグ味等の不快な味及び独特の不快な
臭いを改善し、服用を容易にすることができる内服液組
成物に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an oral liquid composition, and more specifically, it gives an unpleasant taste such as bitterness, astringency, acrid taste and a unique unpleasant odor which the active ingredient of a medicinal food contains. The present invention relates to an oral liquid composition that can be improved and can be taken easily.

【0002】[0002]

【従来の技術】従来から、内服液剤は、服用の容易さか
ら、これまで数多くの製品が開発され、広く実用化され
てきている。この場合、内服液剤に配合する医薬食品有
効成分の不快な呈味を改善したり、独特の臭いをマスキ
ングするため、香料や蔗糖等の甘味剤を配合することが
行われており、ある程度の呈味改善や臭いのマスキング
が図られている。
2. Description of the Related Art Conventionally, many oral liquid preparations have been developed and widely put into practical use because of their ease of administration. In this case, in order to improve the unpleasant taste of the medicinal food active ingredient to be mixed in the oral liquid preparation or to mask the unique odor, it is practiced to add a sweetener such as a fragrance or sucrose to some extent. The taste is improved and the smell is masked.

【0003】しかしながら、依然として美味しく服用す
るという程度まで呈味や臭いを改善することは困難であ
った。このため、疾患を有する患者が、本来連用しなけ
ればならない医薬品の服用を途中でやめたり、小児が医
薬品を吐き出したりすることで必要量が摂取できず、病
気回復の遅延や疾患の悪化が生じるという問題があり、
更なる改善が強く望まれている。
However, it is still difficult to improve the taste and smell to such an extent that they are taken deliciously. For this reason, patients with illness may stop taking medications that they should continue to take during the course of the treatment, or children may spit out medications, resulting in delays in disease recovery and worsening of illness. There is a problem,
Further improvement is strongly desired.

【0004】[0004]

【発明が解決しようとする課題】本発明は、前記従来に
おける諸問題を解決し、以下の目的を達成することを課
題とする。即ち、本発明は、苦味等の不快な呈味や独特
の不快な臭いを有する医薬食品有効成分を配合した内服
液を連用しても、美味しく服用でき、小児に服用させて
も内服液の有する異味・異臭によって、吐き出してしま
うことのない呈味及び臭いが改善された内服液組成物を
提供することを目的とする。
SUMMARY OF THE INVENTION It is an object of the present invention to solve the various problems in the prior art and achieve the following objects. That is, the present invention can be taken deliciously even if an oral solution containing a medicinal food active ingredient having an unpleasant taste such as bitterness or a unique unpleasant odor is continuously administered, and the oral solution even when taken by a child has It is an object of the present invention to provide an oral solution composition in which the taste and odor are prevented from being exhaled due to off-taste and off-odor.

【0005】[0005]

【課題を解決するための手段】本発明者らは、前記課題
を解決するため、種々の甘味料と香料を組み合わせて鋭
意検討を重ねた結果、(a)不快な味や臭いを有する医
薬食品有効成分と、(b)フルーツ系香料と、(c)ア
セスルファムカリウムとステビア抽出物とを一定割合で
配合した甘味料と、を組み合わせることにより、これら
各成分の相乗効果から、呈味質、風味、あと味等が極め
て良好な内服液組成物が得られることを見出し、本発明
を完成するに至った。
[Means for Solving the Problems] In order to solve the above problems, the present inventors have conducted intensive studies in combination with various sweeteners and flavors, and as a result, (a) a pharmaceutical food having an unpleasant taste and smell. By combining an active ingredient, (b) a fruit-based flavor, and (c) a sweetener in which acesulfame potassium and stevia extract are mixed in a fixed ratio, the synergistic effect of each of these ingredients results in a taste and flavor. It was found that an oral liquid composition having an extremely good aftertaste can be obtained, and the present invention has been completed.

【0006】即ち、本発明は、前記課題を解決するた
め、下記の内服液組成物を提供することを目的とする。
That is, an object of the present invention is to provide the following oral solution composition to solve the above problems.

【0007】請求項1の発明は、(a)不快な味や臭い
を有する医薬食品有効成分と、(b)フルーツ系香料
と、(c)アセスルファムカリウムとステビア抽出物と
を、質量比で、アセスルファムカリウム:ステビア抽出
物=10:1〜4となるように配合した甘味料と、を含
有することを特徴とする内服液組成物である。請求項2
の発明は、(a)成分の医薬食品有効成分が、かぜ薬、
解熱剤、鎮痛剤、消炎剤、鎮咳剤、去痰剤、抗ヒスタミ
ン剤、止血剤、生薬、ビタミンB群類及び食品添加物か
ら選ばれる1種又は2種以上である請求項1に記載の内
服液組成物である。請求項3の発明は、(b)成分のフ
ルーツ系香料が、カンキツ系香料、ブドウ系香料、プル
ナス属果実系香料及びリンゴ系香料からなる群より選ば
れる1種又は2種以上である請求項1又は2に記載の内
服液組成物である。請求項4の発明は、(c)成分の甘
味料を内服液組成物全量に対し0.005〜0.3W/
V%配合する請求項1乃至3のいずれかに記載の内服液
組成物である。請求項5の発明は、pHが2〜5である
請求項1乃至4のいずれかに記載の内服液組成物であ
る。
According to the invention of claim 1, (a) a medicinal food active ingredient having an unpleasant taste and smell, (b) a fruit-based flavor, (c) acesulfame potassium and stevia extract in a mass ratio, An oral solution composition comprising: acesulfame potassium: stevia extract = 10: 1 to 4; Claim 2
Of the invention, the active ingredient of medicinal food of component (a) is a cold medicine,
The oral liquid composition according to claim 1, which is one or more selected from antipyretics, analgesics, antiphlogistics, antitussives, expectorants, antihistamines, hemostatics, crude drugs, vitamin B groups and food additives. is there. In the invention of claim 3, the fruit-based flavor of the component (b) is one or more selected from the group consisting of citrus flavor, grape flavor, Prunus fruit flavor and apple flavor. The oral solution composition according to 1 or 2. In the invention of claim 4, the sweetener of the component (c) is 0.005 to 0.3 W / based on the total amount of the oral solution composition.
The oral liquid composition according to any one of claims 1 to 3, which is blended with V%. The invention of claim 5 is the oral liquid composition according to any one of claims 1 to 4, which has a pH of 2 to 5.

【0008】本発明によれば、苦味、渋味、エグ味を有
する不快な呈味の医薬食品有効成分に対して、甘味の早
く発現するアセスルファムカリウムが、早く発現する苦
味等をマスキングする一方、甘味が後に残るステビア抽
出物が服用後遅く発現する渋味、エグ味を抑えることで
呈味が改善すると共に、フルーツ系香料が医薬食品有効
成分の不快臭をマスキングし得、これらの相乗効果によ
って、極めて服用感の良好な呈味を有するようになる。
According to the present invention, acesulfame potassium, which expresses sweetness quickly, masks the bitterness that expresses quickly, while the active ingredient of medicinal foods having unpleasant tastes having bitterness, astringency and astringency is masked. Stevia extract that remains after sweetness develops slowly after ingestion, while improving the taste by suppressing the astringent taste, fruit flavors may mask the unpleasant odor of pharmaceutical food active ingredients, and by these synergistic effects , Having a very pleasant taste.

【0009】また、内服液組成物にステビア抽出物が配
合されない場合には、フルーツ系香料の不快感マスキン
グが十分でなく、ステビア抽出物は、フレーバーエンハ
ンサー(味・臭いの相乗改善剤)としても働いているもの
と推定される。
Further, when Stevia extract is not blended in the oral liquid composition, the unpleasantness masking of the fruit-based flavor is not sufficient, and Stevia extract is also used as a flavor enhancer (synergy improving agent for taste and smell). It is estimated to be working.

【0010】[0010]

【発明の実施の形態】以下、本発明について更に詳しく
説明する。本発明の内服液組成物は、(a)不快な味や
臭いを有する医薬食品有効成分と、(b)フルーツ系香
料と、(c)アセスルファムカリウム及びステビア抽出
物からなる甘味料と、を含有し、必要に応じてその他の
成分を含有する。
BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be described in more detail below. The oral liquid composition of the present invention contains (a) a medicinal food active ingredient having an unpleasant taste and smell, (b) a fruit-based flavor, and (c) a sweetener comprising acesulfame potassium and a stevia extract. However, other components are contained if necessary.

【0011】前記(a)成分の苦味、渋味、エグ味等の
不快な味や独特の不快な臭いを有する医薬食品有効成分
としては、かぜ薬、解熱剤、鎮痛剤、消炎剤、鎮咳剤、
去痰剤、抗ヒスタミン剤、止血剤等の医薬品、生薬、ビ
タミンB群類、食品添加物などが挙げられ、これらは1
種を単独で又は2種以上を組み合わせて用いることがで
きる。
The active ingredient of medicinal foods having an unpleasant taste such as bitterness, astringency, and astringency of the above-mentioned component (a) and a unique unpleasant odor includes cold remedies, antipyretics, analgesics, antiphlogistics, antitussives,
Pharmaceuticals such as expectorants, antihistamines, hemostatics, crude drugs, B vitamins, food additives, etc.
The seeds may be used alone or in combination of two or more.

【0012】前記医薬品としては、例えば、アセトアミ
ノフェン、アスピリン、フェナセチン、メフェナム酸、
アンチピリン、フェニルブタゾン、スルピリン、ジクロ
フェナクナトリウム、イブプロフェン、ケトプロフェ
ン、ナプロキセン、エピリゾール、塩酸チアラミド、イ
ンドメタシン、ペンタゾシン、塩化アセチルコリン、酒
石酸アリメマジン、塩酸シプロヘプタジン、ジフェンヒ
ドラミン、塩酸ジフェンヒドラミン、マレイン酸クロル
フェニラミン、リン酸コデイン、リン酸ジヒドロコデイ
ン、臭化水素酸デキストロメトルファン、クエン酸ペン
トキシベリン、テオフィリン、アミノフィリン、塩酸エ
フェドリン、塩酸エピネフリン、硫酸サルブタモール、
塩酸トリメトキノール、塩酸プロカテロール、塩酸メチ
ルエフェドリン、塩酸フェニルプロパノールアミン、グ
アイフェネシン、トラネキサム酸、無水カフェイン、カ
フェインなどが挙げられ、これらは1種単独で使用して
もよく、2種以上を併用してもよい。
Examples of the above-mentioned pharmaceutical agents include acetaminophen, aspirin, phenacetin, mefenamic acid,
Antipyrine, phenylbutazone, sulpirine, diclofenac sodium, ibuprofen, ketoprofen, naproxen, epirizole, tiaramide hydrochloride, indomethacin, pentazocine, acetylcholine chloride, alimemazine hydrochloride, cyproheptadine hydrochloride, diphenhydramine hydrochloride, diphenhydramine hydrochloride, chlorpheniramine maleate, phosphoric acid phosphate. Dihydrocodeine phosphate, dextromethorphan hydrobromide, pentoxyberine citrate, theophylline, aminophylline, ephedrine hydrochloride, epinephrine hydrochloride, salbutamol sulfate,
Examples include trimethoquinol hydrochloride, procaterol hydrochloride, methylephedrine hydrochloride, phenylpropanolamine hydrochloride, guaifenesin, tranexamic acid, anhydrous caffeine, and caffeine. These may be used alone or in combination of two or more. You may.

【0013】前記生薬としては、例えば、アロエ、ウイ
キョウ、ウコン、ウヤク、エンゴサク、エイジツ、オウ
ギ、オウセイ、オンジ、ガラナ、クコシ、ジオウ、トウ
キ、トチュウ、ニンジン、アマロゲンチン、オウゴン、
オウバク、オウレン、ガジュツ、カスカラサグラダ、カ
ッコウ、カスカリラノキ、カノコ草、カロウコン、キキ
ョウ、キジツ、キョウニン、キハダ、クコ、クジン、ケ
イガイ、ケイヒ、ケツメイシ、ケンゴシ、ゲンチアナ、
ゲンノショウコ、コウジン、コウブシ、コウボク、ゴオ
ウ、ゴシツ、ゴシュユ、ゴミシ、コロンボ、コンズラン
ゴ、サイコ、サンシシ、サフラン、サンズコン、ジオ
ウ、シコン、シソシ、シャクヤク、シャジン(ツリガネ
ニンジン)、シャゼン(オオバコ)、ジャ香、ショウキ
ョウ、ショウマ、セイヒ、セキショウコン、センキュ
ウ、センコツ、センタウリウム草、センブリ、センボ
ウ、センソ、センナ、ソウジュツ、ソウハクヒ、ソヨ
ウ、ダイオウ、竹節人参、チモ、チレッタ草、チンピ、
トウヒ、トウニン、トコン、ニガキ、ニンジン、ビャク
シャク、ビャクジュツ、ベラドンナコン、ヘノポジ油、
ヤクチ、ユウタン、ヨモギ、ニガヨモギ、苦味チンキ、
ジシュユ、ホップ、ホミカ、ボウイ、マオウ、モクツ
ウ、モッコウ、リュウタン、リンドウ、ルソンカ、レン
ギョウ、ニンジン、セネガ、キキョウ、ショウキョウ、
ローヤルゼリーなどが挙げられ、これらは1種単独で使
用してもよく、2種以上を併用してもよい。
The herbal medicines include, for example, aloe, fennel, turmeric, oyster, corydalis, ages, ougi, ousei, onji, guarana, kokushi, swordfish, touki, eucommia, carrot, amarogentin, sardine,
Oataku, Ouren, Gautu, Cascala Sagrada, Cuckoo, Cascalyllaceae, Crapeweed, Crowcon, Ginkgo, Pheasant, Kyounin, Kihada, Kuko, Kujin, Keigai, Keihi, Ketsumeishi, Kengoshi, Gentiana,
Gencho ginger, koujin, kobushi, koboku, gobo, goshitsu, goshuyu, gorushi, colombo, konzlango, psycho, sashishi, saffron, sandscon, dio, shikon, perilla, peony, shazin (tsuraiganenjin), shazen (plantain), jascent, jascent Gourd, gall, seihi, boiled ginger, senkyu, senkotsu, centaurium grass, senburi, senbou, senso, senna, sojutsu, sohakuhi, soyo, daioh, bamboo shoot ginseng, chimo, chillet grass, chimpi,
Spruce, tounin, turmeric, bittern, carrot, juniper, juniper, belladonnacon, henoposite oil,
Yakuchi, yutan, mugwort, mugwort, bitter tincture,
Jisyu, hop, homika, bowie, maoh, mokutsu, mokko, ryutan, gentian, luzonka, forsythia, carrot, senega, kyokyou, ginkgo,
Examples include royal jelly, and these may be used alone or in combination of two or more.

【0014】前記ビタミンB群類としては、例えば、ビ
タミンB群(例えば、チアミン、硝酸チアミン、塩酸
チアミン、ビタミンB誘導体等)、ビタミンB
(例えば、リボフラビン、リン酸リボフラビンナトリウ
ム、酪酸リボフラビン等)、ビタミンB群(例えば、
ピリドキシン、ピリドキサル、ピリドキサミン及びこれ
らのリン酸あるいは塩酸塩等)、ビタミンB12群(例
えば、コバラミン、シアノコバラミン、メチルコバラミ
ン等)などが挙げられ、これらは1種単独で使用しても
よく、2種以上を併用してもよい。
Examples of the vitamin B group include vitamin B 1 group (for example, thiamine, thiamine nitrate, thiamine hydrochloride, vitamin B 1 derivative, etc.), vitamin B 2 group (for example, riboflavin, sodium riboflavin phosphate phosphate, butyric acid). Riboflavin, etc.), vitamin B 6 group (for example,
Pyridoxine, pyridoxal, pyridoxamine and phosphoric acid or hydrochloride thereof, etc., vitamin B 12 group (eg, cobalamin, cyanocobalamin, methylcobalamin, etc.) and the like, and these may be used alone or in combination of two kinds. You may use together the above.

【0015】前記食品添加物としては、例えば、パント
テン酸カルシウム、塩化カリウム、蠣殻末、ナイアシン
アミド、ビオチン、海藻粉末、ニコチン酸アミド、シア
ノコバラミンなどが挙げられ、これらは1種単独で使用
してもよく、2種以上を併用してもよい。
Examples of the above-mentioned food additives include calcium pantothenate, potassium chloride, starch husk powder, niacinamide, biotin, seaweed powder, nicotinic acid amide, cyanocobalamin, and the like. Also, two or more kinds may be used in combination.

【0016】前記(a)成分の不快な味や臭いを有する
医薬食品有効成分は、それぞれの目的に応じて薬効を奏
する有効量の範囲で配合されるが、通常、内服液組成物
全量に対し0.001〜1W/V%配合することが好ま
しい。
The active ingredient of medicinal foods having the unpleasant taste and smell of the above-mentioned component (a) is mixed in an effective amount range which produces a medicinal effect according to each purpose. It is preferable to add 0.001 to 1 W / V%.

【0017】前記(b)成分のフルーツ系香料として
は、例えば、ミカン、オレンジ、レモン、グレープフル
ーツ、シークアーサー等のカンキツ系香料、赤ブドウ、
マスカット等のブドウ系香料、モモ、アプリコット、ウ
メ、アンズ等のプルナス属果実香料、青リンゴ等のリン
ゴ系香料、パッションフルーツ、パイナップル、ライ
チ、バナナ等のトロピカルフルーツ系香料、イチゴ系香
料などが挙げられ、これらは、1種のみで配合しても良
く、2種以上配合することもできる。これらの中でも、
カンキツ系香料、ブドウ系香料、プルナス属果実系香
料、リンゴ系香料が風味の改善が好適である点で特に好
ましい。
Examples of the fruit-based fragrance as the component (b) include citrus-based fragrances such as mandarin orange, orange, lemon, grapefruit, and seaquat, red grape,
Grape flavors such as Muscat, Prunus fruit flavors such as peach, apricot, plum, apricots, apple flavors such as green apples, tropical fruit flavors such as passion fruit, pineapple, lychee and banana, and strawberry flavors. However, these may be blended alone or in combination of two or more. Among these,
Citrus-based flavors, grape-based flavors, Prunus fruit-based flavors, and apple-based flavors are particularly preferable in that they are suitable for improving the flavor.

【0018】前記(b)成分のフルーツ系香料は、内服
液組成物全量に対し、0.001〜1.0W/V%配合
することが好ましく、0.05〜0.5W/V%配合す
ることがより好ましい。
The component (b), the fruit-based flavor, is preferably blended in an amount of 0.001 to 1.0 W / V%, preferably 0.05 to 0.5 W / V%, based on the total amount of the oral liquid composition. Is more preferable.

【0019】前記(c)成分の甘味料は、ステビア抽出
物とアセスルファムカリウムとを混合してなる。ここ
で、前記アセスルファムカリウム及びステビア抽出物の
配合比率は、質量比で、アセスルファムカリウム10に
対し、ステビア抽出物が1〜4であり、特に1.5〜3
であることが好ましい。ステビア抽出物が1未満の場合
には、呈味の改善が十分ではなくなり、一方、4を超え
ると、ステビア抽出物の後甘味が強く出ることで、くど
い甘味を呈し、服用感が悪くなる。
The sweetener (c) is a mixture of stevia extract and acesulfame potassium. Here, the compounding ratio of the acesulfame potassium and the stevia extract is a mass ratio of 1 to 4 stevia extract to 10 parts of acesulfame potassium, and particularly 1.5 to 3
Is preferred. When the amount of Stevia extract is less than 1, the taste is not sufficiently improved. On the other hand, when the amount of Stevia extract is more than 4, the stevia extract has a strong sweetness, resulting in a dull sweetness and a poor feeling of ingestion.

【0020】前記(c)成分のステビア抽出物は、キク
科の多年生植物ステビア(Stevia Rebaud
iana)の葉を抽出精製して甘味成分の純度を80%
以上にしたものであり、砂糖の300倍以上の甘味を有
する天然甘味料である。このステビア抽出物としては、
ステビオサイド、レバウディオサイドA、レバウディオ
サイドC、レバウディオサイドD、レバウディオサイド
E、ズルコサイドA単品及びこれらにグルコシルトラン
スフェラーゼを作用させて得られるα−グルコシル化合
物も含まれる。
The component (c), stevia extract, is a perennial plant of the Asteraceae Stevia Rebaud.
iana) leaves are extracted and purified to have a sweetness component of 80% purity.
The above is a natural sweetener having a sweetness 300 times or more that of sugar. As this Stevia extract,
Also included are stevioside, rebaudioside A, rebaudioside C, rebaudioside D, rebaudioside E, zulcoside A alone, and α-glucosyl compounds obtained by reacting these with glucosyltransferase.

【0021】前記(c)成分のアセスルファムカリウム
〔6−メチル−1,2,3−オキサチアジン−4(3
H)−オン−2,2−ジオキシドのカリウム塩(C
KNOS、分子量:201.24)〕は、下記の構
造式を有する合成甘味料であり、5%蔗糖水溶液と比較
したとき蔗糖の約200倍の甘味度を有する。
Acesulfame potassium [6-methyl-1,2,3-oxathiazine-4 (3) as the component (c).
H) -one-2,2-dioxide potassium salt (C 4 H
4 KNO 4 S, molecular weight: 201.24)] is a synthetic sweetener having the following structural formula, and has a sweetness of about 200 times that of sucrose when compared to a 5% sucrose aqueous solution.

【0022】[0022]

【化1】 [Chemical 1]

【0023】前記(c)成分のアセスルファムカリウム
及びステビア抽出物からなる甘味料は、内服液組成物中
の不快な味や臭いを有する成分により、配合量を加減す
ることもできるが、内服液組成物に対し、0.005〜
0.3W/V%、好ましくは0.01〜0.15W/V
%である。前記アセスルファムカリウム及びステビア抽
出物の配合量が0.005W/V%未満の場合は、呈味
改善効果が十分でなくなり、一方、0.3W/V%を超
えると、甘味が強すぎてくどい味となり、服用が困難と
なる場合がある。
The sweetener consisting of the acesulfame potassium and the stevia extract of the above-mentioned component (c) can be blended in an amount depending on the components having an unpleasant taste and odor in the oral liquid composition. 0.005-
0.3 W / V%, preferably 0.01 to 0.15 W / V
%. When the compounding amount of the acesulfame potassium and the stevia extract is less than 0.005 W / V%, the taste improving effect becomes insufficient, while when it exceeds 0.3 W / V%, the sweetness is too strong and the taste is dull. , And it may be difficult to take.

【0024】なお、本発明の内服液組成物の呈味改善効
果を疎外しない程度であれば、(c)成分の甘味料以外
にも、甘味のボリューム感を出すために、果糖、蔗糖、
ブドウ糖、麦芽糖等の糖質甘味料を配合しても良く、更
に甘味の爽快感を出すために、マルチトール、キシリト
ール、エリスリトール、ソルビトール、マンニトール等
の糖アルコール類、アスパルテーム、シエクラロース、
サッカリン等の高甘味度甘味料を配合しても良い。
In addition to the sweetener as the component (c), fructose, sucrose, and other ingredients may be used as long as the taste improving effect of the oral liquid composition of the present invention is not excluded.
Glucose, maltose and other sugar sweeteners may be blended, and in order to provide a refreshing sweetness, sugar alcohols such as maltitol, xylitol, erythritol, sorbitol, mannitol, aspartame, syclarose,
You may mix | blend high intensity sweeteners, such as saccharin.

【0025】本発明の内服液組成物は、前記(a)〜
(c)の必要成分を含むと共に、酸を用いて液性のpH
を2〜5にし、酸味を強化することで、爽快感を強化し
て、より一層服用し易い呈味に改善することができる。
この場合、前記内服液組成物のpHを2〜5に調整する
ためには、pH調整剤として、例えば、酢酸、クエン
酸、リンゴ酸、酒石酸、アスコルビン酸等の有機酸やリ
ン酸を用いることが好ましい。
The oral liquid composition of the present invention comprises the above (a) to
A liquid pH containing the necessary components of (c) and using an acid
2 to 5 to enhance the sourness, the refreshing feeling can be enhanced and the taste can be more easily taken.
In this case, in order to adjust the pH of the oral solution composition to 2 to 5, for example, an organic acid such as acetic acid, citric acid, malic acid, tartaric acid, ascorbic acid, or phosphoric acid is used as a pH adjuster. Is preferred.

【0026】前記その他の成分としては、特に制限はな
く、目的に応じて適宜選定することができるが、例え
ば、防腐剤、保存剤、着香剤、芳香剤、清涼化剤、界面
活性剤、可溶化剤、乳化剤、溶剤、緩衝剤、懸濁剤、粘
稠剤、着色剤、安定化剤、溶解補助剤などが挙げられ、
これらは1種単独で使用してもよく、2種以上を併用し
てもよい。
The above-mentioned other components are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include preservatives, preservatives, fragrances, fragrances, cooling agents, surfactants, Solubilizers, emulsifiers, solvents, buffers, suspensions, thickeners, colorants, stabilizers, solubilizers and the like,
These may be used alone or in combination of two or more.

【0027】前記防腐剤、保存剤としては、例えば、ソ
ルビン酸ナトリウム、安息香酸類(安息香酸、安息香酸
ナトリウム等)、パラベン類(パラオキシ安息香酸エチ
ル、パラオキシ安息香酸ブチル、パラオキシ安息香酸プ
ロピル等)などが挙げられる。
Examples of the preservatives and preservatives include sodium sorbate, benzoic acids (benzoic acid, sodium benzoate, etc.), parabens (ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, etc.), etc. Is mentioned.

【0028】前記界面活性剤、可溶化剤、乳化剤、及
び、溶剤としては、例えば、ショ糖脂肪酸エステル、ポ
リオキシエチレン硬化ヒマシ油類、ポリソルベート類及
びプルロニック類等の非イオン性界面活性剤、エタノー
ル、注射用蒸留水、精製水などが挙げられる。
Examples of the surfactants, solubilizers, emulsifiers, and solvents include nonionic surfactants such as sucrose fatty acid esters, polyoxyethylene hydrogenated castor oils, polysorbates and pluronics, and ethanol. , Distilled water for injection, purified water and the like.

【0029】前記懸濁剤、粘稠剤としては、例えば、ア
ラビアゴム、結晶セルロース、ビーガム、キサンタンガ
ム、ゼラチン、メトロース及びその可食性塩、カルメロ
ース及びその可食性塩などが挙げられる。前記着色剤と
しては、例えば、カラメル、β−カロチン、各種食用色
素(食用黄色1号、食用赤色2号等)などが挙げられ
る。前記安定化剤としては、例えば、エデト酸の可食性
塩、塩化ナトリウム、及び、ピロ亜硫酸の可食性塩など
が挙げられる。
Examples of the suspending agent and thickening agent include gum arabic, crystalline cellulose, bee gum, xanthan gum, gelatin, metrose and edible salts thereof, carmellose and edible salts thereof, and the like. Examples of the colorant include caramel, β-carotene, various food colors (food yellow No. 1, food red No. 2, etc.) and the like. Examples of the stabilizer include an edible salt of edetic acid, sodium chloride, and an edible salt of pyrosulfite.

【0030】前記その他の成分(防腐剤、保存剤、着香
剤、芳香剤、清涼化剤、界面活性剤、可溶化剤、乳化
剤、溶剤、緩衝剤、懸濁剤、粘稠剤、着色剤、安定化
剤、及び、溶解補助剤等)の、内服液組成物における含
有量としては、特に制限はなく、従来の経口液剤に配合
される量で適宜含有されるのが好ましい。
Other ingredients (preservatives, preservatives, flavors, fragrances, cooling agents, surfactants, solubilizers, emulsifiers, solvents, buffers, suspending agents, thickeners, coloring agents) , Stabilizers, solubilizing agents, etc.) in the oral liquid composition are not particularly limited, and are preferably appropriately contained in the conventional oral solutions.

【0031】前記内服液組成物の調製方法としては、特
に制限はなく、通常、各成分と精製水等の溶剤の一部と
を混合、溶解し、残りの溶剤を加えて液量を調製し、必
要に応じて、酸又はアルカリを用いてpHを調整する。
The method for preparing the oral solution composition is not particularly limited, and each component is usually mixed with a part of a solvent such as purified water and dissolved, and the remaining solvent is added to prepare a liquid amount. If necessary, the pH is adjusted using acid or alkali.

【0032】本発明の内服液組成物は、液状形態で経口
投与される医薬品、医薬部外品、健康食品であればよ
く、液剤(例えばシロップ剤、ドリンク剤)、懸濁剤、
乳剤、顆粒剤、散剤、カプセル剤などに製剤化すること
ができ、医薬用途としては、滋養強壮剤、感胃用剤、解
熱鎮痛剤、気管支拡張剤等、内服液剤の形で用いられる
ものに適用できる。
The oral liquid composition of the present invention may be a drug, quasi drug, or health food that is orally administered in a liquid form, such as a liquid agent (for example, syrup or drink), a suspension,
It can be formulated into emulsions, granules, powders, capsules, etc., and is used for medicinal purposes such as nourishing tonics, gastric-sensing agents, antipyretic analgesics, bronchodilators, etc. Applicable.

【0033】[0033]

【実施例】以下、実施例を挙げて、本発明を更に具体的
に説明するが、本発明は、下記実施例に何ら限定される
ものではない。
The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples.

【0034】〔実施例1〕 内服液剤 下記表1に示す成分と、精製水とポリオキシ硬化ヒマシ
油と安息香酸ナトリウムとを加え、更にクエン酸でpH
を3.4に調整した後100mLとして、本発明品1〜
2及び比較品1〜4の内服液剤を製造した。
[Example 1] Oral solution Add the ingredients shown in Table 1 below, purified water, polyoxy hydrogenated castor oil and sodium benzoate, and further add citric acid to adjust the pH.
Of the present invention 1
2 and comparative liquids 1 to 4 were manufactured.

【0035】次に、各内服液剤について、パネラー17
名による、苦味・渋味・エグ味、後味の良さ、前
味の良さ、独特の不快感、の4項目についての官能評
価を下記評価基準に従って行い、評価結果の平均値を算
出した。結果を表1に示す。
Next, the panelists 17 for each oral liquid preparation
The sensory evaluation of the four items of bitterness / astringency / astringency, good aftertaste, good front taste, and unique discomfort by name was performed according to the following evaluation criteria, and the average value of the evaluation results was calculated. The results are shown in Table 1.

【0036】<評価基準> 5点:優れる 4点:やや優れる 3点:普通 2点:やや劣る 1点:劣る<Evaluation criteria> 5 points: excellent 4 points: somewhat excellent 3 points: Normal 2 points: somewhat inferior 1 point: inferior

【0037】[0037]

【表1】 [Table 1]

【0038】〔実施例2〕 内服シロップ 下記表2に示す成分と、精製水とポリオキシエチレン硬
化ヒマシ油と安息香酸ナトリウムを加え、更にクエン酸
でpHを調整して100mLとして、本発明品3〜4及
び比較品5〜7の内服シロップを製造した。
[Example 2] Oral syrup The components shown in Table 2 below, purified water, polyoxyethylene hydrogenated castor oil and sodium benzoate were added, and the pH was adjusted to 100 mL with citric acid to prepare the product 3 of the present invention. 4 and comparative products 5 to 7 were manufactured.

【0039】次に、各内服シロップについて、パネラー
18名による、苦味・渋味・エグ味、後味の良さ、
前味の良さ、独特の不快感、の4項目についての官
能評価を上記実施例1と同様に行い、評価結果の平均値
を算出した。結果を表2に示す。
Next, for each oral syrup, 18 panelists selected the bitterness, astringency, astringency, and good aftertaste.
The sensory evaluations of the four items of the good taste and unique discomfort were performed in the same manner as in Example 1 above, and the average value of the evaluation results was calculated. The results are shown in Table 2.

【0040】[0040]

【表2】 [Table 2]

【0041】〔実施例3〕 内服液剤 下記表3に示す成分と、ポリオキシエチレン硬化ヒマシ
油と安息香酸ナトリウムと精製水を加え、更にクエン酸
でpHを3.5に調整し、実施例3の内服液剤50mL
を得た。
[Example 3] Oral liquid agent The components shown in Table 3 below, polyoxyethylene hydrogenated castor oil, sodium benzoate and purified water were added, and the pH was adjusted to 3.5 with citric acid. 50 mL of oral liquid
Got

【0042】[0042]

【表3】 [Table 3]

【0043】〔実施例4〕 内服液剤 下記表4に示す成分と、プロピレングリコールと安息香
酸ナトリウムと精製水を加え、更にクエン酸でpHを4
とし、実施例4の内服液剤50mLを得た。
[Example 4] Oral liquid formulation The components shown in Table 4 below, propylene glycol, sodium benzoate and purified water were added, and the pH was adjusted to 4 with citric acid.
As a result, 50 mL of the oral liquid preparation of Example 4 was obtained.

【0044】[0044]

【表4】 [Table 4]

【0045】〔実施例5〕 内服液剤 下記表5に示す成分と、ポリオキシエチレン硬化ヒマシ
油と安息香酸ナトリウムと精製水を加え、更にクエン酸
でpHを3.2に調整し、実施例5の内服液剤30mL
を得た。
[Example 5] Oral liquid agent The components shown in Table 5 below, polyoxyethylene hydrogenated castor oil, sodium benzoate and purified water were added, and the pH was adjusted to 3.2 with citric acid. Oral liquid medicine 30mL
Got

【0046】[0046]

【表5】 [Table 5]

【0047】上記実施例3〜5の内服液剤は、いずれも
医薬食品有効成分の苦味等の不快な呈味や独特の不快な
臭いが抑えられ、美味しく服用できるものであった。
Each of the oral liquid preparations of Examples 3 to 5 was able to be taken deliciously because unpleasant tastes such as bitterness of the active ingredient of medicinal foods and unique unpleasant odors were suppressed.

【0048】[0048]

【発明の効果】以上説明したように、本発明によれば、
苦味等の不快な呈味や独特の不快な臭いを有する医薬食
品有効成分を配合した内服液を連用しても、美味しく服
用でき、小児に服用させても内服液の有する異味・異臭
によって、吐き出してしまうということのない呈味及び
臭いの改善された内服液組成物が得られる。
As described above, according to the present invention,
It can be taken deliciously even if an oral solution containing a medicinal food active ingredient having an unpleasant taste such as bitterness or a unique unpleasant odor is continuously administered, and it is exhaled due to the offensive taste and odor of the oral solution even when administered to children. An oral liquid composition with improved taste and odor that does not end up being obtained is obtained.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 47/12 A61K 47/12 47/14 47/14 47/26 47/26 47/46 47/46 A61P 11/00 A61P 11/00 // A61K 31/137 A61K 31/137 31/167 31/167 31/4402 31/4402 31/485 31/485 31/522 31/522 Fターム(参考) 4B018 MD61 MD94 ME14 MF02 4C076 AA22 BB01 CC01 CC03 CC09 CC15 DD08F DD41R DD46F DD61T DD68T FF12 FF16 FF39 FF52 FF61 4C086 AA01 AA02 BC17 CB07 CB23 MA03 MA05 MA23 MA52 NA09 ZA59 ZC75 4C206 AA01 AA02 FA10 GA02 GA31 MA03 MA05 MA43 MA72 NA09 ZA59 ZC75 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 47/12 A61K 47/12 47/14 47/14 47/26 47/26 47/46 47/46 A61P 11/00 A61P 11/00 // A61K 31/137 A61K 31/137 31/167 31/167 31/4402 31/4402 31/485 31/485 31/522 31/522 F term (reference) 4B018 MD61 MD94 ME14 MF02 4C076 AA22 BB01 CC01 CC03 CC09 CC15 DD08F DD41R DD46F DD61T DD68T FF12 FF16 FF39 FF52 FF61 4C086 AA01 AA02 BC17 CB07 CB23 MA03 MA05 MA23 MA52 NA09 MA03 NA03 MA03 NA03 MA03 NA03 MA03 NA03 MA03 NA03 MA10 NA02 MA10 NA03 MA10

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 (a)不快な味や臭いを有する医薬食品
有効成分と、(b)フルーツ系香料と、(c)アセスル
ファムカリウムとステビア抽出物を、質量比で、アセス
ルファムカリウム:ステビア抽出物=10:1〜4とな
るように配合した甘味料と、を含有することを特徴とす
る内服液組成物。
1. Acesulfame potassium: stevia extract in a mass ratio of (a) a medicinal food active ingredient having an unpleasant taste and smell, (b) a fruit-based flavor, and (c) acesulfame potassium and stevia extract in a mass ratio. = 10: 1 to 4 and a sweetener blended so as to be contained therein.
【請求項2】 (a)成分の医薬食品有効成分が、かぜ
薬、解熱剤、鎮痛剤、消炎剤、鎮咳剤、去痰剤、抗ヒス
タミン剤、止血剤、生薬、ビタミンB群類及び食品添加
物から選ばれる1種又は2種以上である請求項1に記載
の内服液組成物。
2. The active ingredient of medicinal food of component (a) is selected from cold medicines, antipyretics, analgesics, antiphlogistics, antitussives, expectorants, antihistamines, hemostatics, herbal medicines, vitamin B group and food additives. The oral liquid composition according to claim 1, which is one kind or two or more kinds.
【請求項3】 (b)成分のフルーツ系香料が、カンキ
ツ系香料、ブドウ系香料、プルナス属果実系香料及びリ
ンゴ系香料からなる群より選ばれる1種又は2種以上で
ある請求項1又は2に記載の内服液組成物。
3. The fruit-based flavor as the component (b) is one or more selected from the group consisting of citrus-based flavor, grape-based flavor, Prunus fruit-based flavor and apple-based flavor. The oral liquid composition according to 2.
【請求項4】 (c)成分の甘味料を内服液組成物全量
に対し0.005〜0.3W/V%配合する請求項1乃
至3のいずれかに記載の内服液組成物。
4. The internal-use liquid composition according to claim 1, wherein the sweetener as the component (c) is added in an amount of 0.005 to 0.3 W / V% based on the total amount of the internal-use liquid composition.
【請求項5】 pHが2〜5である請求項1乃至4のい
ずれかに記載の内服液組成物。
5. The oral liquid composition according to claim 1, which has a pH of 2 to 5.
JP2002027757A 2002-02-05 2002-02-05 Oral liquid composition Expired - Fee Related JP4190769B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002027757A JP4190769B2 (en) 2002-02-05 2002-02-05 Oral liquid composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002027757A JP4190769B2 (en) 2002-02-05 2002-02-05 Oral liquid composition

Publications (2)

Publication Number Publication Date
JP2003231647A true JP2003231647A (en) 2003-08-19
JP4190769B2 JP4190769B2 (en) 2008-12-03

Family

ID=27773398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002027757A Expired - Fee Related JP4190769B2 (en) 2002-02-05 2002-02-05 Oral liquid composition

Country Status (1)

Country Link
JP (1) JP4190769B2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006055074A (en) * 2004-08-20 2006-03-02 Takeda-Kirin Foods Corp Hop extract-containing composition
JP2007063144A (en) * 2005-08-29 2007-03-15 Taisho Pharmaceut Co Ltd Liquid composition
JP2009517044A (en) * 2005-11-23 2009-04-30 ザ・コカ−コーラ・カンパニー High-intensity sweetener composition containing anti-inflammatory agent and composition sweetened thereby
EP2386209A2 (en) 2010-05-11 2011-11-16 Jungbunzlauer Austria AG Natural sweetener
JP2012143243A (en) * 2007-03-14 2012-08-02 Concentrate Manufacturing Co Of Ireland Diet beverage products comprising rebaudioside a, erythritol or tagatose and acidulant
WO2013129436A1 (en) * 2012-02-29 2013-09-06 武田薬品工業株式会社 Oral agent
JP2014070055A (en) * 2012-09-28 2014-04-21 Kobayashi Pharmaceutical Co Ltd Liquid pharmaceutical composition for oral administration
US8900644B2 (en) * 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
JP2018123099A (en) * 2017-02-02 2018-08-09 エルメッド エーザイ株式会社 Pharmaceutical composition containing vildagliptin, method of suppressing odor of vildagliptin in pharmaceutical composition, and odor suppressor of vildagliptin in pharmaceutical composition
WO2020175274A1 (en) * 2019-02-27 2020-09-03 株式会社ヤクルト本社 Food/beverage product, off-flavor masking agent for food/beverage product, and off-flavor masking method for food/beverage product
KR20210110450A (en) 2020-02-28 2021-09-08 주식회사 종근당 Multi-vitamins complex composition with improved compliance and preparation method for the same
KR102622231B1 (en) 2022-07-01 2024-01-08 주식회사 종근당 PHARMACEUTICAL COMPOSITION OF MULTI-VITAMINS COMPLEX FOR IMPROVING APPEARANCE STABILITY USING iSTab(innovative Stability Technology by antimoisture barrier) TECHNOLOGY

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006055074A (en) * 2004-08-20 2006-03-02 Takeda-Kirin Foods Corp Hop extract-containing composition
US8900644B2 (en) * 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
JP2007063144A (en) * 2005-08-29 2007-03-15 Taisho Pharmaceut Co Ltd Liquid composition
JP2009517044A (en) * 2005-11-23 2009-04-30 ザ・コカ−コーラ・カンパニー High-intensity sweetener composition containing anti-inflammatory agent and composition sweetened thereby
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
JP2012143243A (en) * 2007-03-14 2012-08-02 Concentrate Manufacturing Co Of Ireland Diet beverage products comprising rebaudioside a, erythritol or tagatose and acidulant
EP2386209A2 (en) 2010-05-11 2011-11-16 Jungbunzlauer Austria AG Natural sweetener
WO2013129436A1 (en) * 2012-02-29 2013-09-06 武田薬品工業株式会社 Oral agent
JP2014070055A (en) * 2012-09-28 2014-04-21 Kobayashi Pharmaceutical Co Ltd Liquid pharmaceutical composition for oral administration
JP2018123099A (en) * 2017-02-02 2018-08-09 エルメッド エーザイ株式会社 Pharmaceutical composition containing vildagliptin, method of suppressing odor of vildagliptin in pharmaceutical composition, and odor suppressor of vildagliptin in pharmaceutical composition
WO2020175274A1 (en) * 2019-02-27 2020-09-03 株式会社ヤクルト本社 Food/beverage product, off-flavor masking agent for food/beverage product, and off-flavor masking method for food/beverage product
JPWO2020175274A1 (en) * 2019-02-27 2020-09-03
JP7512247B2 (en) 2019-02-27 2024-07-08 株式会社ヤクルト本社 Food and drink, food and drink off-flavor masking agent, and method for masking off-flavor of food and drink
KR20210110450A (en) 2020-02-28 2021-09-08 주식회사 종근당 Multi-vitamins complex composition with improved compliance and preparation method for the same
KR102622231B1 (en) 2022-07-01 2024-01-08 주식회사 종근당 PHARMACEUTICAL COMPOSITION OF MULTI-VITAMINS COMPLEX FOR IMPROVING APPEARANCE STABILITY USING iSTab(innovative Stability Technology by antimoisture barrier) TECHNOLOGY

Also Published As

Publication number Publication date
JP4190769B2 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
JP2874967B2 (en) Pharmaceutical water suspension for drug actives essentially insoluble in water
JP4726269B2 (en) Oral solution
DE69719827T2 (en) SUPPRESSION OF UNWANTED TASTE IN ORAL COMPILATIONS
KR101490721B1 (en) Liquid Formulation for Deferiprone With Palatable Taste
KR101551506B1 (en) Medical composition containing rebamipide
JP2003231647A (en) Oral liquid composition
JP2818220B2 (en) Composition containing water-containing organic solvent extract for food, composition containing water-containing organic solvent extract for medicine, and methods for producing them
JP2003026576A (en) Medicine having improved taste
JP2010209029A (en) Pharmaceutical composition or health food with improved taste
JPH09501421A (en) Pharmaceutical composition containing a drug / β-cyclodextrin complex in combination with an acid-base couple
JP2002363105A (en) Method for masking unpleasant taste and solution for oral administration
JP2004161679A (en) Liquid preparation for internal use
JP2002080369A (en) Thiamine derivative-containing composition
JP4068442B2 (en) Taste improving composition
JP5083492B2 (en) Liquid for internal use
JP2003171314A (en) Oral administration solution composition
JP2004175672A (en) Oral liquid agent containing glycyrrhizinic acid
JPH09286724A (en) Liquid stablizer for oral administration
JP5009707B2 (en) Solution for oral administration of quinolone antibacterial agent masked with unpleasant taste
JP5928331B2 (en) Dimemorphan-containing oral solution
JP4889948B2 (en) An oral solution with excellent ingestion
JPH0827034A (en) Liquid agent for internal use containing erythritol
JPH10167988A (en) Oral liquid preparation
JP4990515B2 (en) Isosorbide preparation with improved taste quality
JPH09286723A (en) Improved oral solution

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080902

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080917

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110926

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4190769

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120926

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120926

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130926

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees